skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: assunto: Animals remover assunto: Pharmacology. Drug Treatments remover Biological And Medical Sciences remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
Material Type:
Artigo 		Adicionar ao Meu Espaço

Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

LEWIS PHILLIPS, Gail D ; FIELDS, Carter T ; DIERAS, Veronique ; CRIVELLARI, Diana ; LIANG FANG ; GUARDINO, Ellie ; OLSEN, Steven R ; CROCKER, Lisa M ; SLIWKOWSKI, Mark X ; GUANGMIN LI ; DOWBENKO, Donald ; SCHAEFER, Gabriele ; MILLER, Kathy ; ANDRE, Fabrice ; BURRIS, Howard A ; ALBAIN, Kathy S ; HARBECK, Nadia

Clinical cancer research, 2014-01, Vol.20 (2), p.456-468 [Periódico revisado por pares]

Philadelphia, PA: American Association for Cancer Research

Texto completo disponível

Citações Citado por
2
Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

JUNUTULA, Jagath R ; FLAGELLA, Kelly M ; MAI, Elaine ; LEWIS PHILLIPS, Gail D ; HIRARAGI, Hajime ; FUJI, Reina N ; TIBBITTS, Jay ; VANDLEN, Richard ; SPENCER, Susan D ; SCHELLER, Richard H ; POLAKIS, Paul ; SLIWKOWSKI, Mark X ; GRAHAM, Richard A ; PARSONS, Kathryn L ; HA, Edward ; RAAB, Helga ; BHAKTA, Sunil ; NGUYEN, Trung ; DUGGER, Debra L ; GUANGMIN LI

Clinical cancer research, 2010-10, Vol.16 (19), p.4769-4778 [Periódico revisado por pares]

Philadelphia, PA: American Association for Cancer Research

Texto completo disponível

Citações Citado por
3
Navitoclax (ABT‐263) and bendamustine ± rituximab induce enhanced killing of non‐Hodgkin's lymphoma tumours in vivo
Navitoclax (ABT‐263) and bendamustine ± rituximab induce enhanced killing of non‐Hodgkin's lymphoma tumours in vivo
Material Type:
Artigo 		Adicionar ao Meu Espaço

Navitoclax (ABT‐263) and bendamustine ± rituximab induce enhanced killing of non‐Hodgkin's lymphoma tumours in vivo

Ackler, S ; Mitten, MJ ; Chen, J ; Clarin, J ; Foster, K ; Jin, S ; Phillips, DC ; Schlessinger, S ; Wang, B ; Leverson, JD ; Boghaert, ER

British journal of pharmacology, 2012-10, Vol.167 (4), p.881-891 [Periódico revisado por pares]

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
4
Developmental Programming: Deficits in Reproductive Hormone Dynamics and Ovulatory Outcomes in Prenatal, Testosterone-Treated Sheep
Developmental Programming: Deficits in Reproductive Hormone Dynamics and Ovulatory Outcomes in Prenatal, Testosterone-Treated Sheep
Material Type:
Artigo 		Adicionar ao Meu Espaço

Developmental Programming: Deficits in Reproductive Hormone Dynamics and Ovulatory Outcomes in Prenatal, Testosterone-Treated Sheep

Veiga-Lopez, A ; Ye, W ; Phillips, D.J ; Herkimer, C ; Knight, P.G ; Padmanabhan, V

Biology of reproduction, 2008-04, Vol.78 (4), p.636-647 [Periódico revisado por pares]

Madison, WI: Society for the Study of Reproduction, Inc

Texto completo disponível

Citações Citado por
5
Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates
Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates
Material Type:
Artigo 		Adicionar ao Meu Espaço

Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates

Wada, Russ ; Erickson, Hans K. ; Lewis Phillips, Gail D. ; Provenzano, Carmela A. ; Leipold, Douglas D. ; Mai, Elaine ; Johnson, Holly ; Tibbitts, Jay

Cancer chemotherapy and pharmacology, 2014-11, Vol.74 (5), p.969-980 [Periódico revisado por pares]

Berlin/Heidelberg: Springer Berlin Heidelberg

Texto completo disponível

Citações Citado por
6
Understanding the genotoxicity of tamoxifen?
Understanding the genotoxicity of tamoxifen?
Material Type:
Artigo 		Adicionar ao Meu Espaço

Understanding the genotoxicity of tamoxifen?

PHILLIPS, David H

Carcinogenesis (New York), 2001-06, Vol.22 (6), p.839-849 [Periódico revisado por pares]

Oxford: Oxford University Press

Texto completo disponível

Citações Citado por
7
Development of Ruthenium Antitumor Drugs that Overcome Multidrug Resistance Mechanisms
Development of Ruthenium Antitumor Drugs that Overcome Multidrug Resistance Mechanisms
Material Type:
Artigo 		Adicionar ao Meu Espaço

Development of Ruthenium Antitumor Drugs that Overcome Multidrug Resistance Mechanisms

Vock, Carsten A ; Ang, Wee Han ; Scolaro, Claudine ; Phillips, Andrew D ; Lagopoulos, Lucienne ; Juillerat-Jeanneret, Lucienne ; Sava, Gianni ; Scopelliti, Rosario ; Dyson, Paul J

Journal of medicinal chemistry, 2007-05, Vol.50 (9), p.2166-2175 [Periódico revisado por pares]

Washington, DC: American Chemical Society

Texto completo disponível

Citações Citado por
8
Platelet glycoprotein IIb/IIIa antagonists : What are the relevant issues concerning their pharmacology and clinical use?
Platelet glycoprotein IIb/IIIa antagonists : What are the relevant issues concerning their pharmacology and clinical use?
Material Type:
Artigo 		Adicionar ao Meu Espaço

Platelet glycoprotein IIb/IIIa antagonists : What are the relevant issues concerning their pharmacology and clinical use?

SCARBOROUGH, R. M ; KLEIMAN, N. S ; PHILLIPS, D. R

Circulation (New York, N.Y.), 1999-07, Vol.100 (4), p.437-444 [Periódico revisado por pares]

Hagerstown, MD: Lippincott Williams & Wilkins

Texto completo disponível

Citações Citado por
9
Clinical Pharmacology of Eptifibatide
Clinical Pharmacology of Eptifibatide
Material Type:
Artigo 		Adicionar ao Meu Espaço

Clinical Pharmacology of Eptifibatide

Phillips, David R ; Scarborough, Robert M

The American journal of cardiology, 1997-08, Vol.80 (4), p.11B-20B [Periódico revisado por pares]

New York, NY: Elsevier Inc

Texto completo disponível

Citações Citado por
10
Synthesis and Pharmacology of Conformationally Restricted Raloxifene Analogues:  Highly Potent Selective Estrogen Receptor Modulators
Synthesis and Pharmacology of Conformationally Restricted Raloxifene Analogues:  Highly Potent Selective Estrogen Receptor Modulators
Material Type:
Artigo 		Adicionar ao Meu Espaço

Synthesis and Pharmacology of Conformationally Restricted Raloxifene Analogues:  Highly Potent Selective Estrogen Receptor Modulators

Grese, Timothy A. ; Pennington, Lewis D. ; Sluka, James P. ; Adrian, M. Dee ; Cole, Harlan W. ; Fuson, Tina R. ; Magee, David E. ; Phillips, D. Lynn ; Rowley, Ellen R. ; Shetler, Pamela K. ; Short, Lorri L. ; Venugopalan, Murali ; Yang, Na N. ; Sato, Masahiko ; Glasebrook, Andrew L. ; Bryant, Henry U.

Journal of medicinal chemistry, 1998-04, Vol.41 (8), p.1272-1283 [Periódico revisado por pares]

Washington, DC: American Chemical Society

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (177)

Data de Publicação 

De até
Refinar
  1. Antes de1989  (17)
  2. 1989Até1994  (23)
  3. 1995Até2000  (66)
  4. 2001Até2007  (58)
  5. Após 2007  (18)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.